Crossject S.A.
ALCJ.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$79.12M
Close$
$-0.28
121.7% downside
Current Fair Value
121.7% downsideOvervalued by 121.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $79.12 Million |
|---|---|
| Enterprise Value | $85.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.2 |
| Beta | 0.52 |
| Outstanding Shares | 60,014,000 |
Return
| Return on Equity | -851.34% |
|---|---|
| Return on Assets | -71.19% |
| Return on Invested Capital | -63.99% |
Valuation & Multiples
| P/E Ratio | -5.28 |
|---|---|
| PEG | -6.94 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 88.58 |
| Enterprise Value to EBIT | -4.8 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 6.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Crossject S.A.
99 employees
CEO: Patrick Alexandre Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively adv...